Issue navigation
Volume 104, Issue 9, 2 May 2012
IN THIS ISSUE
IN THIS ISSUE
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Page 639, https://doi.org/10.1093/jnci/djs230
MEMO TO THE MEDIA
Breast Cancer Risk after False-Positive Mammography Results
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Page NP, https://doi.org/10.1093/jnci/djs228
DNA Repair Pathway Score for Predicting Chemotherapy Response in Ovarian Cancer Patients
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Page NP, https://doi.org/10.1093/jnci/djs234
EDITORIALS
Unraveling Genes, Hormones, and Breast Cancer
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 641–642, https://doi.org/10.1093/jnci/djs193
Molecular Scores to Predict Ovarian Cancer Outcomes: A Worthy Goal, but Not Ready for Prime Time
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 642–645, https://doi.org/10.1093/jnci/djs203
Is 15-LOX-1 a Tumor Suppressor?
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 645–647, https://doi.org/10.1093/jnci/djs192
NEWS
The Promise of Protons in Cancer Therapy
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 648–649, https://doi.org/10.1093/jnci/djs238
Macrophages: Cancer Therapy’s Double-Edged Sword
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 649–652, https://doi.org/10.1093/jnci/djs235
Getting It Right: BPA and the Difficulty Proving Environmental Cancer Risks
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 652–655, https://doi.org/10.1093/jnci/djs237
StatBite Age-Specific Mammography Screening Results
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Page 654, https://doi.org/10.1093/jnci/djs236
Physician Data Query (PDQ®) Update
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 655–656, https://doi.org/10.1093/jnci/djs231
ARTICLES
CYP3A Variation, Premenopausal Estrone Levels, and Breast Cancer Risk
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 657–669, https://doi.org/10.1093/jnci/djs156
A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 670–681, https://doi.org/10.1093/jnci/djs177
Risk of Breast Cancer After False-Positive Test Results in Screening Mammography
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 682–689, https://doi.org/10.1093/jnci/djs176
Vitamin D–Related Genetic Variation, Plasma Vitamin D, and Risk of Lethal Prostate Cancer: A Prospective Nested Case–Control Study
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 690–699, https://doi.org/10.1093/jnci/djs189
Staging and Functional Characterization of Pheochromocytoma and Paraganglioma by 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 700–708, https://doi.org/10.1093/jnci/djs188
BRIEF COMMUNICATION
Effects of Gut-Targeted 15-LOX-1 Transgene Expression on Colonic Tumorigenesis in Mice
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 709–716, https://doi.org/10.1093/jnci/djs187
CORRESPONDENCE
Re: Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Page 717, https://doi.org/10.1093/jnci/djs162
Response: Re: Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Page 717, https://doi.org/10.1093/jnci/djs163
Re: Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Pages 717–718, https://doi.org/10.1093/jnci/djs164
Response: Re: Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Page 718, https://doi.org/10.1093/jnci/djs166
COVER
Cover
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Page NP, https://doi.org/10.1093/jnci/djs121
STANDING MATERIALS
TABLE OF CONTENTS
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Page NP, https://doi.org/10.1093/jnci/djs124
EDITORIAL BOARD
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Page NP, https://doi.org/10.1093/jnci/djs122
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
JNCI: Journal of the National Cancer Institute, Volume 104, Issue 9, 2 May 2012, Page NP, https://doi.org/10.1093/jnci/djs123
